查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1402920

血友病治療藥物市場（產品：重組凝血因子濃縮物、血漿衍生凝血因子濃縮物等）- 2023-2031 年全球產業分析、規模、佔有率、成長、趨勢和預測

Hemophilia Treatment Drugs Market (Product: Recombinant Coagulation Factor Concentrates, Plasma-derived Coagulation Factor Concentrates, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 188 Pages | 商品交期: 2-10個工作天內

價格

血友病治療藥物市場 - 報告範圍

TMR 關於全球血友病治療藥物市場的報告研究了過去以及當前的成長趨勢和機會，以獲得 2023 年至 2031 年預測期內市場指標的寶貴見解。該報告提供了全球血友病治療藥物的收入2017-2031年期間的市場，考慮2023年為基準年，2031年為預測年。報告中也提供了2023年至2031年全球血友病治療藥物市場的年複合成長率（CAGR %）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解血友病治療藥物市場。

市場概況
2023年市場價值 118 億美元
2031 年市場價值 186 億美元
CAGR 5%

該報告深入探討了全球血友病治療藥物市場的競爭格局。全球血友病治療藥物市場的主要參與者已經確定，並且每個參與者都根據各種屬性進行了分析。公司概況、財務狀況、最新發展和 SWOT 是本報告中介紹的全球血友病治療藥物市場參與者的屬性。

目錄

第 1 章：執行摘要

第 2 章：假設與研究方法

第 3 章：執行摘要：全球市場

第 4 章：市場概述

  • 市場區隔
  • 概述
  • 市場動態
  • 2023-2031年全球市場分析與預測

第 5 章：關鍵見解

  • 管道分析
  • 類型清單
  • 全球主要國家的疾病盛行率和發生率
  • COVID-19 大流行對該行業的影響

第 6 章：全球市場分析與預測：依產品分類

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：按產品，2023-2031
    • 重組凝血因子濃縮物
      • 因子VIII
      • 因子IX
      • 其他
    • 血漿衍生凝血因子濃縮物
      • 因子VIII
      • 因子IX
      • 其他
    • 其他
  • 市場吸引力：依產品分類

第 7 章：全球市場分析與預測：按疾病適應症

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：依疾病適應症，2023-2031
    • 甲型血友病
    • 乙型血友病
    • 其他
  • 市場吸引力：依疾病適應症分類

第 8 章：全球市場分析與預測：按配銷通路

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：按配銷通路，2023-2031
    • 醫院藥房
    • 零售藥局
    • 網路藥局
  • 市場吸引力：按配銷通路

第 9 章：全球市場分析與預測：按地區

  • 主要發現
  • 市場價值預測：按地區，2023-2031
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力：按地區

第 10 章：北美市場分析與預測

第 11 章：歐洲市場分析與預測

第 12 章：亞太市場分析與預測

第 13 章：拉丁美洲市場分析與預測

第 14 章：中東和非洲市場分析與預測

第 15 章：競爭格局

  • 市場參與者 - 競爭矩陣（依公司層級和規模）
  • 市佔率分析：依公司分類（2022 年）
  • 公司簡介
    • Pfizer Inc.
    • CSL Behring
    • Kedrion
    • Takeda Pharmaceutical Company Limited
    • Novo Nordisk A/S
    • Bayer AG
    • F. Hoffmann-La Roche Ltd.
    • Octapharma AG
    • Biotest AG
    • Sanofi SA
Product Code: TMRGL1900

Hemophilia Treatment Drugs Market - Scope of Report

TMR's report on the global hemophilia treatment drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global hemophilia treatment drugs market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global hemophilia treatment drugs market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the hemophilia treatment drugs market.

Market Snapshot
Market Value in 2023US$ 11.8 Bn
Market Value in 2031US$ 18.6 Bn
CAGR5%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global hemophilia treatment drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global hemophilia treatment drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global hemophilia treatment drugs market.

The report delves into the competitive landscape of the global hemophilia treatment drugs market. Key players operating in the global hemophilia treatment drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global hemophilia treatment drugs market profiled in this report.

Key Questions Answered in Global hemophilia treatment drugs Market Report:

  • What is the sales/revenue generated by hemophilia treatment drugs across all regions during the forecast period?
  • What are the opportunities in the global hemophilia treatment drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Hemophilia Treatment Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global hemophilia treatment drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global hemophilia treatment drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global hemophilia treatment drugs market.

Table of Contents

1. Executive Summary

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Hemophilia Treatment Drugs Market

4. Market Overview

  • 4.1. Market Segmentation
    • 4.1.1. Segment Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Hemophilia Treatment Drugs Market Analysis and Forecast, 2023-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. List of Types of Hemophilia Treatment Drugs
  • 5.3. Disease Prevalence & Incidence Rate Globally with Key Countries
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Product

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Product, 2023-2031
    • 6.3.1. Recombinant Coagulation Factor Concentrates
      • 6.3.1.1. Factor VIII
      • 6.3.1.2. Factor IX
      • 6.3.1.3. Others
    • 6.3.2. Plasma-derived Coagulation Factor Concentrates
      • 6.3.2.1. Factor VIII
      • 6.3.2.2. Factor IX
      • 6.3.2.3. Others
    • 6.3.3. Others
  • 6.4. Market Attractiveness, by Product

7. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Disease Indication

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Disease Indication, 2023-2031
    • 7.3.1. Hemophilia A
    • 7.3.2. Hemophilia B
    • 7.3.3. Others
  • 7.4. Market Attractiveness, by Disease Indication

8. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction and Definitions
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2023-2031
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness, by Distribution Channel

9. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2023-2031
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness, by Region

10. North America Hemophilia Treatment Drugs Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Product, 2023-2031
    • 10.2.1. Recombinant Coagulation Factor Concentrates
      • 10.2.1.1. Factor VIII
      • 10.2.1.2. Factor IX
      • 10.2.1.3. Others
    • 10.2.2. Plasma-derived Coagulation Factor Concentrates
      • 10.2.2.1. Factor VIII
      • 10.2.2.2. Factor IX
      • 10.2.2.3. Others
    • 10.2.3. Others
  • 10.3. Market Attractiveness, by Product
  • 10.4. Market Value Forecast, by Disease Indication, 2023-2031
    • 10.4.1. Hemophilia A
    • 10.4.2. Hemophilia B
    • 10.4.3. Others
  • 10.5. Market Attractiveness, by Disease Indication
  • 10.6. Market Value Forecast, by Distribution Channel, 2023-2031
    • 10.6.1. Hospital Pharmacies
    • 10.6.2. Retail Pharmacies
    • 10.6.3. Online Pharmacies
  • 10.7. Market Attractiveness, by Distribution Channel
  • 10.8. Market Value Forecast, by Country, 2023-2031
    • 10.8.1. U.S.
    • 10.8.2. Canada
  • 10.9. Market Attractiveness Analysis
    • 10.9.1. By Product
    • 10.9.2. By Disease Indication
    • 10.9.3. By Distribution Channel
    • 10.9.4. By Country

11. Europe Hemophilia Treatment Drugs Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
    • 11.1.2. Recombinant Coagulation Factor Concentrates
      • 11.1.2.1. Factor VIII
      • 11.1.2.2. Factor IX
      • 11.1.2.3. Others
    • 11.1.3. Plasma-derived Coagulation Factor Concentrates
      • 11.1.3.1. Factor VIII
      • 11.1.3.2. Factor IX
      • 11.1.3.3. Others
    • 11.1.4. Others
  • 11.2. Market Attractiveness, by Product
  • 11.3. Market Value Forecast, by Disease Indication, 2023-2031
    • 11.3.1. Hemophilia A
    • 11.3.2. Hemophilia B
    • 11.3.3. Others
  • 11.4. Market Attractiveness, by Disease Indication
  • 11.5. Market Value Forecast, by Distribution Channel, 2023-2031
    • 11.5.1. Hospital Pharmacies
    • 11.5.2. Retail Pharmacies
    • 11.5.3. Online Pharmacies
  • 11.6. Market Attractiveness, by Distribution Channel
  • 11.7. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 11.7.1. Germany
    • 11.7.2. U.K.
    • 11.7.3. France
    • 11.7.4. Italy
    • 11.7.5. Spain
    • 11.7.6. Rest of Europe
  • 11.8. Market Attractiveness Analysis
    • 11.8.1. By Product
    • 11.8.2. By Disease Indication
    • 11.8.3. By Distribution Channel
    • 11.8.4. By Country/Sub-region

12. Asia Pacific Hemophilia Treatment Drugs Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Product, 2023-2031
    • 12.2.1. Recombinant Coagulation Factor Concentrates
      • 12.2.1.1. Factor VIII
      • 12.2.1.2. Factor IX
      • 12.2.1.3. Others
    • 12.2.2. Plasma-derived Coagulation Factor Concentrates
      • 12.2.2.1. Factor VIII
      • 12.2.2.2. Factor IX
      • 12.2.2.3. Others
    • 12.2.3. Others
  • 12.3. Market Attractiveness, by Product
  • 12.4. Market Value Forecast, by Disease Indication, 2023-2031
    • 12.4.1. Hemophilia A
    • 12.4.2. Hemophilia B
    • 12.4.3. Others
  • 12.5. Market Attractiveness, by Disease Indication
  • 12.6. Market Value Forecast, by Distribution Channel, 2023-2031
    • 12.6.1. Hospital Pharmacies
    • 12.6.2. Retail Pharmacies
    • 12.6.3. Online Pharmacies
  • 12.7. Market Attractiveness, by Distribution Channel
  • 12.8. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 12.8.1. China
    • 12.8.2. Japan
    • 12.8.3. India
    • 12.8.4. Australia & New Zealand
    • 12.8.5. Rest of Asia Pacific
  • 12.9. Market Attractiveness Analysis
    • 12.9.1. By Product
    • 12.9.2. By Disease Indication
    • 12.9.3. By Distribution Channel
    • 12.9.4. By Country/Sub-region

13. Latin America Hemophilia Treatment Drugs Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Product, 2023-2031
    • 13.2.1. Recombinant Coagulation Factor Concentrates
      • 13.2.1.1. Factor VIII
      • 13.2.1.2. Factor IX
      • 13.2.1.3. Others
    • 13.2.2. Plasma-derived Coagulation Factor Concentrates
      • 13.2.2.1. Factor VIII
      • 13.2.2.2. Factor IX
      • 13.2.2.3. Others
    • 13.2.3. Others
  • 13.3. Market Attractiveness, by Product
  • 13.4. Market Value Forecast, by Disease Indication, 2023-2031
    • 13.4.1. Hemophilia A
    • 13.4.2. Hemophilia B
    • 13.4.3. Others
  • 13.5. Market Attractiveness, by Disease Indication
  • 13.6. Market Value Forecast, by Distribution Channel, 2023-2031
    • 13.6.1. Hospital Pharmacies
    • 13.6.2. Retail Pharmacies
    • 13.6.3. Online Pharmacies
  • 13.7. Market Attractiveness, by Distribution Channel
  • 13.8. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 13.8.1. Brazil
    • 13.8.2. Mexico
    • 13.8.3. Rest of Latin America
  • 13.9. Market Attractiveness Analysis
    • 13.9.1. By Product
    • 13.9.2. By Disease Indication
    • 13.9.3. By Distribution Channel
    • 13.9.4. By Country/Sub-region

14. Middle East & Africa Hemophilia Treatment Drugs Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Product, 2023-2031
    • 14.2.1. Recombinant Coagulation Factor Concentrates
      • 14.2.1.1. Factor VIII
      • 14.2.1.2. Factor IX
      • 14.2.1.3. Others
    • 14.2.2. Plasma-derived Coagulation Factor Concentrates
      • 14.2.2.1. Factor VIII
      • 14.2.2.2. Factor IX
      • 14.2.2.3. Others
    • 14.2.3. Others
  • 14.3. Market Attractiveness, by Product
  • 14.4. Market Value Forecast, by Disease Indication, 2023-2031
    • 14.4.1. Hemophilia A
    • 14.4.2. Hemophilia B
    • 14.4.3. Others
  • 14.5. Market Attractiveness, by Disease Indication
  • 14.6. Market Value Forecast, by Distribution Channel, 2023-2031
    • 14.6.1. Hospital Pharmacies
    • 14.6.2. Retail Pharmacies
    • 14.6.3. Online Pharmacies
  • 14.7. Market Attractiveness, by Distribution Channel
  • 14.8. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 14.8.1. GCC Countries
    • 14.8.2. South Africa
    • 14.8.3. Rest of Middle East & Africa
  • 14.9. Market Attractiveness Analysis
    • 14.9.1. By Product
    • 14.9.2. By Disease Indication
    • 14.9.3. By Distribution Channel
    • 14.9.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2022)
  • 15.3. Company Profiles
    • 15.3.1. Pfizer Inc.
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. Financial Overview
      • 15.3.1.4. SWOT Analysis
      • 15.3.1.5. Strategic Overview
    • 15.3.2. CSL Behring
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. Financial Overview
      • 15.3.2.4. SWOT Analysis
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Kedrion
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. Financial Overview
      • 15.3.3.4. SWOT Analysis
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Takeda Pharmaceutical Company Limited
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. Financial Overview
      • 15.3.4.4. SWOT Analysis
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Novo Nordisk A/S
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. Financial Overview
      • 15.3.5.4. SWOT Analysis
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Bayer AG
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. Financial Overview
      • 15.3.6.4. SWOT Analysis
      • 15.3.6.5. Strategic Overview
    • 15.3.7. F. Hoffmann-La Roche Ltd.
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. Financial Overview
      • 15.3.7.4. SWOT Analysis
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Octapharma AG
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. Financial Overview
      • 15.3.8.4. SWOT Analysis
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Biotest AG
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. Financial Overview
      • 15.3.9.4. SWOT Analysis
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Sanofi S.A.
      • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. Financial Overview
      • 15.3.10.4. SWOT Analysis
      • 15.3.10.5. Strategic Overview

List of Tables

  • Table 1: Global Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Product, 2023-2031
  • Table 2: Global Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Disease Indication, 2023-2031
  • Table 3: Global Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2023-2031
  • Table 4: Global Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Region, 2023-2031
  • Table 5: North America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Country, 2023-2031
  • Table 6: North America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Product, 2023-2031
  • Table 7: North America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Disease Indication, 2023-2031
  • Table 8: North America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2023-2031
  • Table 9: Europe Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2023-2031
  • Table 10: Europe Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Product, 2023-2031
  • Table 11: Europe Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Disease Indication, 2023-2031
  • Table 12: Europe Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Distribution Channel 2023-2031
  • Table 13: Asia Pacific Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2023-2031
  • Table 14: Asia Pacific Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Product, 2023-2031
  • Table 15: Asia Pacific Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Disease Indication, 2023-2031
  • Table 16: Asia Pacific Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2023-2031
  • Table 17: Latin America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2023-2031
  • Table 18: Latin America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Product, 2023-2031
  • Table 19: Latin America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Disease Indication, 2023-2031
  • Table 20: Latin America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Distribution Channel 2023-2031
  • Table 21: Middle East & Africa Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2023-2031
  • Table 22: Middle East & Africa Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Product, 2023-2031
  • Table 23: Middle East & Africa Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Disease Indication, 2023-2031
  • Table 24: Middle East & Africa Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Distribution Channel 2023-2031

List of Figures

  • Figure 1: Global Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, 2023-2031
  • Figure 2: Global Hemophilia Treatment Drugs Market Value Share, by Product, 2022
  • Figure 3: Global Hemophilia Treatment Drugs Market Value Share, by Disease Indication, 2022
  • Figure 4: Global Hemophilia Treatment Drugs Market Value Share, by Distribution Channel, 2022
  • Figure 5: Global Hemophilia Treatment Drugs Market Value Share Analysis, by Product, 2022 and 2031
  • Figure 6: Global Hemophilia Treatment Drugs Market Attractiveness Analysis, by Product, 2023-2031
  • Figure 7: Global Hemophilia Treatment Drugs Market Value Share Analysis, by Disease Indication, 2022 and 2031
  • Figure 8: Global Hemophilia Treatment Drugs Market Attractiveness Analysis, by Disease Indication, 2023-2031
  • Figure 9: Global Hemophilia Treatment Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 10: Global Hemophilia Treatment Drugs Market Attractiveness Analysis, by Distribution Channel 2023-2031
  • Figure 11: Global Hemophilia Treatment Drugs Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 12: Global Hemophilia Treatment Drugs Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 13: North America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, 2023-2031
  • Figure 14: North America Hemophilia Treatment Drugs Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 15: North America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 16: North America Hemophilia Treatment Drugs Market Value Share Analysis, by Product, 2022 and 2031
  • Figure 17: North America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Product, 2023-2031
  • Figure 18: North America Hemophilia Treatment Drugs Market Value Share Analysis, by Disease Indication, 2022 and 2031
  • Figure 19: North America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Disease Indication, 2023-2031
  • Figure 20: North America Hemophilia Treatment Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 21: North America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Distribution Channel 2023-2031
  • Figure 22: Europe Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, 2023-2031
  • Figure 23: Europe Hemophilia Treatment Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 24: Europe Hemophilia Treatment Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 25: Europe Hemophilia Treatment Drugs Market Value Share Analysis, by Product, 2022 and 2031
  • Figure 26: Europe America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Product, 2023-2031
  • Figure 27: Europe Hemophilia Treatment Drugs Market Value Share Analysis, by Disease Indication, 2022 and 2031
  • Figure 28: Europe Hemophilia Treatment Drugs Market Attractiveness Analysis, by Disease Indication, 2023-2031
  • Figure 29: Europe Hemophilia Treatment Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 30: Europe Hemophilia Treatment Drugs Market Attractiveness Analysis, by Distribution Channel 2023-2031
  • Figure 31: Asia Pacific Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, 2023-2031
  • Figure 32: Asia Pacific Hemophilia Treatment Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 33: Asia Pacific Hemophilia Treatment Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 34: Asia Pacific Hemophilia Treatment Drugs Market Value Share Analysis, by Product, 2022 and 2031
  • Figure 35: Asia Pacific Hemophilia Treatment Drugs Market Attractiveness Analysis, by Product, 2023-2031
  • Figure 36: Asia Pacific Hemophilia Treatment Drugs Market Value Share Analysis, by Disease Indication, 2022 and 2031
  • Figure 37: Asia Pacific Hemophilia Treatment Drugs Market Attractiveness Analysis, by Disease Indication, 2023-2031
  • Figure 38: Asia Pacific Hemophilia Treatment Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 39: Asia Pacific Hemophilia Treatment Drugs Market Attractiveness Analysis, by Distribution Channel 2023-2031
  • Figure 40: Latin America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, 2023-2031
  • Figure 41: Latin America Hemophilia Treatment Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 42: Latin America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 43: Latin America Hemophilia Treatment Drugs Market Value Share Analysis, by Product, 2022 and 2031
  • Figure 44: Latin America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Product, 2023-2031
  • Figure 45: Latin America Hemophilia Treatment Drugs Market Value Share Analysis, by Disease Indication, 2022 and 2031
  • Figure 46: Latin America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Disease Indication, 2023-2031
  • Figure 47: Latin America Hemophilia Treatment Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 48: Latin America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 49: Middle East & Africa Hemophilia Treatment Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 50: Middle East & Africa Hemophilia Treatment Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 51: Middle East & Africa America Hemophilia Treatment Drugs Market Value Share Analysis, by Product, 2023-2031
  • Figure 52: Middle East & Africa America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Product, 2023-2031
  • Figure 53: Middle East & Africa Hemophilia Treatment Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 54: Middle East & Africa Hemophilia Treatment Drugs Market Attractiveness Analysis, by Distribution Channel 2023-2031
  • Figure 55: Global Hemophilia Treatment Drugs Market Share Analysis, by Company (2022)